Skip to main content
Lineage Cell Therapeutics Inc. logo

Lineage Cell Therapeutics Inc. — Investor Relations & Filings

Ticker · LCTX ISIN · US53566P1093 LEI · 5299002BI4W22SDF8R25 TA Manufacturing
Open in API
Filings indexed 2,777 across all filing types
Latest filing 2024-11-24 Regulatory Filings
Country US United States of America
Listing TA LCTX

About Lineage Cell Therapeutics Inc.

https://lineagecell.com/

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel allogeneic cell therapies for unmet medical needs. The company's proprietary platform uses directed differentiation of pluripotent stem cells to manufacture specialized human cells. These "off-the-shelf" cell transplants are designed to replace or support dysfunctional cells in patients with serious conditions, aiming to restore or enhance physiological function. The therapeutic pipeline is focused on degenerative diseases of the eye, such as dry age-related macular degeneration, and neurological conditions, including spinal cord injury. The company leverages its integrated capabilities in cell line development, manufacturing, and delivery to advance its programs.

Recent filings

Filing Released Lang Actions
Lineage entered into securities purchase agreements relating to the purchase and sale of common shares and warrants
Regulatory Filings Classification · 98% confidence The document explicitly identifies itself as a "FORM 8-K" and a "CURRENT REPORT" filed pursuant to the Securities Exchange Act of 1934. Item 1.01 details the entry into a material definitive agreement (securities purchase agreements for a registered direct offering), and Item 7.01 references a press release announcing the pricing of this offering. Form 8-K filings report material, unscheduled events. While the definitions provided do not explicitly list 'Form 8-K', the content—reporting a significant financing/capital event (Item 1.01) and referencing a press release (Item 7.01)—is a core function of current reports. Since 'Form 8-K' is not a direct code option, the most appropriate classification among the choices for a significant, unscheduled corporate action filing that isn't a standard periodic report (10-K, IR) or a specific announcement (DIV, MANG) is the general regulatory fallback category, RNS (Regulatory Filings), as 8-K is a fundamental SEC filing type.
2024-11-24 English
Lineage entered into securities purchase agreements relating to the purchase and sale of common shares and warrants
Capital/Financing Update Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly mentions entering into 'securities purchase agreements' and states that an '8-K-24-11-2024_isa.pdf' is attached, which details the transaction. An 8-K filing in the US context reports significant current events, often related to financing or material corporate changes. Since this document is announcing a material transaction (securities purchase agreements) and refers to an attached PDF detailing the event, it fits best under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Given the specific nature of entering into securities purchase agreements, CAP is more precise than the general RNS fallback. However, the document structure strongly suggests it is an announcement *about* a filing (like an 8-K) rather than the full financial report itself. Since 'CAP' covers financing activities, and this is an announcement of a financing/securities transaction, I will classify it as CAP, but note the short length and reference to an attachment suggests it could also be RPA/RNS if the content was purely administrative. Because the core subject is a securities purchase agreement, CAP is the most relevant specific category.
2024-11-24 English
4
Director's Dealing
2024-11-22 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-22 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under a registration statement, describing an offering of common shares and warrants. It details the terms of the offering, placement agent information, shareholder approval conditions, and related legal and financial disclosures. This type of document is a capital raising disclosure related to financing activities, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update filings.
2024-11-21 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a securities purchase agreement for a registered direct offering of common shares and warrants. It details the terms of the offering, expected proceeds, use of proceeds, and related agreements. There are no financial statements or detailed financial performance data included, only disclosures about financing activities and agreements. This fits the definition of a Capital/Financing Update, which covers updates on company fundraising and capital structure changes. The document length is over 13,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-11-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.